Linked Life Data

2474772

Source:http://linkedlifedata.com/resource/pubmed/id/2474772

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2474772rdf:typepubmed:Citationlld:pubmed
pubmed-article:2474772lifeskim:mentionsumls-concept:C0026896lld:lifeskim
pubmed-article:2474772lifeskim:mentionsumls-concept:C0205147lld:lifeskim
pubmed-article:2474772lifeskim:mentionsumls-concept:C0034792lld:lifeskim
pubmed-article:2474772lifeskim:mentionsumls-concept:C0004358lld:lifeskim
pubmed-article:2474772lifeskim:mentionsumls-concept:C0872192lld:lifeskim
pubmed-article:2474772lifeskim:mentionsumls-concept:C1542147lld:lifeskim
pubmed-article:2474772lifeskim:mentionsumls-concept:C1521840lld:lifeskim
pubmed-article:2474772lifeskim:mentionsumls-concept:C0332120lld:lifeskim
pubmed-article:2474772pubmed:issue8lld:pubmed
pubmed-article:2474772pubmed:dateCreated1989-9-8lld:pubmed
pubmed-article:2474772pubmed:abstractTextWe investigated specificities of acetylcholine receptor (AChR) antibodies in 100 seropositive patients with myasthenia gravis (MG). Antibodies in 74 of these sera were inhibited by more than 50% from binding to human muscle AChR by a rat monoclonal antibody (mAb) of "main immunogenic region" (MIR) specificity. The mAb inhibition was not explainable by epitope competition because (1) the mAb was reactive with both Torpedo and human AChR, but antibodies in 85 of the MG sera did not bind to Torpedo AChR, and (2) the mAb blocked binding of rat anti-peptide antibodies to an alpha subunit region of the human AChR unrelated antigenically to the designated MIR region. Individual patients' sera had evidence of extensive antibody heterogeneity and revealed interspecies polymorphisms in AChR antigenicity, near and remote from the neurotransmitter-binding region. The data challenge the concept that a MIR of the AChR is the principal stimulus for antibody production in MG and emphasize a potential pitfall in assuming seronegativity in MG on the basis of a single assay system.lld:pubmed
pubmed-article:2474772pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2474772pubmed:languageenglld:pubmed
pubmed-article:2474772pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2474772pubmed:citationSubsetAIMlld:pubmed
pubmed-article:2474772pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2474772pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2474772pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2474772pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2474772pubmed:statusMEDLINElld:pubmed
pubmed-article:2474772pubmed:monthAuglld:pubmed
pubmed-article:2474772pubmed:issn0028-3878lld:pubmed
pubmed-article:2474772pubmed:authorpubmed-author:GriesmannG...lld:pubmed
pubmed-article:2474772pubmed:authorpubmed-author:LennonV AVAlld:pubmed
pubmed-article:2474772pubmed:issnTypePrintlld:pubmed
pubmed-article:2474772pubmed:volume39lld:pubmed
pubmed-article:2474772pubmed:ownerNLMlld:pubmed
pubmed-article:2474772pubmed:authorsCompleteYlld:pubmed
pubmed-article:2474772pubmed:pagination1069-76lld:pubmed
pubmed-article:2474772pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:2474772pubmed:meshHeadingpubmed-meshheading:2474772-...lld:pubmed
pubmed-article:2474772pubmed:meshHeadingpubmed-meshheading:2474772-...lld:pubmed
pubmed-article:2474772pubmed:meshHeadingpubmed-meshheading:2474772-...lld:pubmed
pubmed-article:2474772pubmed:meshHeadingpubmed-meshheading:2474772-...lld:pubmed
pubmed-article:2474772pubmed:meshHeadingpubmed-meshheading:2474772-...lld:pubmed
pubmed-article:2474772pubmed:meshHeadingpubmed-meshheading:2474772-...lld:pubmed
pubmed-article:2474772pubmed:meshHeadingpubmed-meshheading:2474772-...lld:pubmed
pubmed-article:2474772pubmed:meshHeadingpubmed-meshheading:2474772-...lld:pubmed
pubmed-article:2474772pubmed:meshHeadingpubmed-meshheading:2474772-...lld:pubmed
pubmed-article:2474772pubmed:meshHeadingpubmed-meshheading:2474772-...lld:pubmed
pubmed-article:2474772pubmed:meshHeadingpubmed-meshheading:2474772-...lld:pubmed
pubmed-article:2474772pubmed:meshHeadingpubmed-meshheading:2474772-...lld:pubmed
pubmed-article:2474772pubmed:meshHeadingpubmed-meshheading:2474772-...lld:pubmed
pubmed-article:2474772pubmed:meshHeadingpubmed-meshheading:2474772-...lld:pubmed
pubmed-article:2474772pubmed:meshHeadingpubmed-meshheading:2474772-...lld:pubmed
pubmed-article:2474772pubmed:meshHeadingpubmed-meshheading:2474772-...lld:pubmed
pubmed-article:2474772pubmed:year1989lld:pubmed
pubmed-article:2474772pubmed:articleTitleEvidence against acetylcholine receptor having a main immunogenic region as target for autoantibodies in myasthenia gravis.lld:pubmed
pubmed-article:2474772pubmed:affiliationDepartment of Immunology, Mayo Clinic, Rochester, MN 55905.lld:pubmed
pubmed-article:2474772pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2474772pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:2474772pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:2474772pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2474772lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2474772lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2474772lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2474772lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2474772lld:pubmed